iBio announced that it has,
along with Caliber Biotherapeutics, designated a proprietary fusion protein for
cancer treatment as the first product target for advancement on the iBioLaunch
platform, under the licenses and collaboration agreement between the two
companies that was dated Feb. 14, 2013.
“In addition to its other
attributes, iBio technology produces antibodies efficiently,” said iBio
President Robert Erwin. “We are confident our technology will prove superior to
traditional animal cell methods for efficient delivery of this promising new
class of fusion-protein biotherapeutics, and we look forward to working with
Caliber to rapidly move this molecule into clinical trials.”
Collaborating with iBio
gives Caliber additional resources to quickly optimize its production system.
Caliber has an advantage in mAb development and large-scale production; the
company does not have to develop a new cell line for each mAb construct.
Additionally, Caliber’s bioreactors are individual plants, so the company does
not have to scale up to larger reactor components. Caliber just grows 2.2
million individual bioreactors, if necessary, which allows very rapid process
and clinical development and shortens the time to scale large production and,
ultimately, time to market.
The agreement between iBio
and Caliber stipulates that iBio will receive license and milestone fees for
the development of product targets. Caliber is responsible to fund clinical
development and commercialization of such collaboration products. iBio is
entitled to royalties on such product sales and other revenues. The companies
have not disclosed detailed financial terms of the agreement.
For more information, visit
www.ibioinc.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
